Session

Overview: This is a Symposium focused on the multimodal approach to oligometastatic breast disease aiming to explore the state-of-the-art of treatments mainly based on the biology of breast disease and site(s) of metastases (cranial and extracranial). Locoregional treatment of the primary tumour and all metastatic sites usually does not take into account the various biological profiles, while systemic anticancer therapies, immunotherapy and drug-radiation combinations do. The incidence of brain metastases in breast cancer patients is increasing. However, breast cancer patients with brain metastases represent a heterogeneous population, and the prognosis is highly dependent on the systemic disease. A review of the rationale for stereotactic body radiation in low burden metastatic disease and the potential clinical settings in which it can be applied will be made. Discussion of data relating to oncological and toxicity endpoints is crucial. We aim to give a practical summary of the current clinical and trial landscape in oligometastatic breast cancer, highlighting discussion of future perspectives.